Sten Nilsson

14.8k total citations · 1 hit paper
263 papers, 7.8k citations indexed

About

Sten Nilsson is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Sten Nilsson has authored 263 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 150 papers in Pulmonary and Respiratory Medicine, 105 papers in Radiology, Nuclear Medicine and Imaging and 74 papers in Oncology. Recurrent topics in Sten Nilsson's work include Prostate Cancer Treatment and Research (116 papers), Radiopharmaceutical Chemistry and Applications (88 papers) and Prostate Cancer Diagnosis and Treatment (47 papers). Sten Nilsson is often cited by papers focused on Prostate Cancer Treatment and Research (116 papers), Radiopharmaceutical Chemistry and Applications (88 papers) and Prostate Cancer Diagnosis and Treatment (47 papers). Sten Nilsson collaborates with scholars based in Sweden, United States and United Kingdom. Sten Nilsson's co-authors include Øyvind S. Bruland, Per A. Peterson, Roy H. Larsen, Joe M. O’Sullivan, Oliver Sartor, Jan‐Erik Westlin, Per‐Uno Malmström, Nicholas J. Vogelzang, Bo Lennernäs and Amir Sherif and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and The EMBO Journal.

In The Last Decade

Sten Nilsson

257 papers receiving 7.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

2014 290 citations Peter Hoskin, Oliver Sartor et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Sten Nilsson	4.2k	2.8k	2.6k	1.6k	1.5k	263	7.8k
Jürgen E. Gschwend	5.9k 1.4×	3.3k 1.2×	2.1k 0.8×	1.9k 1.2×	2.4k 1.6×	314	10.1k
Alan Horwich	5.6k 1.3×	1.5k 0.5×	2.6k 1.0×	2.0k 1.3×	2.4k 1.6×	140	10.4k
Phillip D. Stricker	5.6k 1.3×	1.9k 0.7×	1.1k 0.4×	1.4k 0.9×	940 0.6×	187	8.2k
Michael A. Gorin	5.9k 1.4×	2.6k 0.9×	1.8k 0.7×	2.3k 1.5×	2.3k 1.5×	327	9.3k
Thomas Wiegel	8.2k 1.9×	1.7k 0.6×	1.8k 0.7×	838 0.5×	1.9k 1.2×	232	10.5k
В. Б. Матвеев	6.1k 1.4×	992 0.4×	1.5k 0.6×	1.0k 0.7×	1.2k 0.8×	184	7.4k
David F. Jarrard	5.0k 1.2×	1.3k 0.5×	2.1k 0.8×	4.0k 2.6×	920 0.6×	207	10.0k
Nobuo Shinohara	2.6k 0.6×	1.0k 0.4×	1.2k 0.4×	1.7k 1.1×	1.6k 1.0×	318	6.2k
Manfred P. Wirth	4.9k 1.2×	800 0.3×	1.6k 0.6×	2.2k 1.4×	2.3k 1.5×	442	9.3k
Gerald P. Murphy	5.9k 1.4×	1.4k 0.5×	3.1k 1.2×	2.0k 1.3×	2.1k 1.4×	321	10.8k

Countries citing papers authored by Sten Nilsson

Since Specialization

Citations

This map shows the geographic impact of Sten Nilsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sten Nilsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sten Nilsson more than expected).

Fields of papers citing papers by Sten Nilsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sten Nilsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sten Nilsson. The network helps show where Sten Nilsson may publish in the future.

Co-authorship network of co-authors of Sten Nilsson

This figure shows the co-authorship network connecting the top 25 collaborators of Sten Nilsson. A scholar is included among the top collaborators of Sten Nilsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sten Nilsson. Sten Nilsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gallo-Oller, Gabriel, Teresita Díaz de Ståhl, Ayodele Alaiya, et al.. (2023). Cytotoxicity of poly-guanidine in medulloblastoma cell lines. Investigational New Drugs. 41(5). 688–698.

Saad, Fred, Silke Gillessen, Daniel Heinrich, et al.. (2019). Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clinical Genitourinary Cancer. 17(5). 348–355.e5. 23 indexed citations

Saad, Fred, Axel Heidenreich, Daniel Heinrich, et al.. (2016). Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP). Annals of Oncology. 27. vi254–vi254. 1 indexed citations

Heinrich, Daniel, Silke Gillessen, Axel Heidenreich, et al.. (2016). Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP). Annals of Oncology. 27. vi255–vi255. 4 indexed citations

Paganelli, Giovanni, Giuseppe Procopio, Enrico Cortesi, et al.. (2016). Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP). Annals of Oncology. 27. iv35–iv35. 5 indexed citations

Nilsson, Sten, Paul Cislo, Oliver Sartor, et al.. (2016). Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Annals of Oncology. 27(5). 868–874. 132 indexed citations

Amadori, D., Claudio Rossetti, Massimo Aglietta, et al.. (2015). 3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA. Annals of Oncology. 26. vi54–vi54. 4 indexed citations

Peng, Zheng, Lambert Skoog, Henrik Hellborg, et al.. (2014). An expression signature at diagnosis to estimate prostate cancer patients’ overall survival. Prostate Cancer and Prostatic Diseases. 17(1). 81–90. 33 indexed citations

Parker, Chris, Daniel Heinrich, David Bottomley, et al.. (2013). Effects of radium-223 dichloride (Ra-223) on health-related quality of life (QOL) outcomes in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) and bone metastases. European Journal of Cancer. 49. 2 indexed citations

10.

Widmark, Anders, Svein Inge Helle, Nicola James, et al.. (2013). Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases. European Journal of Nuclear Medicine and Molecular Imaging. 40.

11.

Persson, Ulf, Sten Nilsson, C Prütz, & Catharina Hjortsberg. (2013). Cost Effectiveness Analysis Of Abiraterone Acetate As Treatment For Metastatic Castration Resistant Prostate Cancer After Failure Of Docetaxel Using Data From Real Life Treatment Praxis In Sweden. Value in Health. 16(3). A134–A135. 1 indexed citations

12.

Wiklund, Peter, Stefan Carlsson, Gabriella Cohn‐Cedermark, et al.. (2012). Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: Single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy. International Journal of Oncology. 42(1). 109–117. 12 indexed citations

13.

Persson, Ulf, Sten Nilsson, Catharina Hjortsberg, & C Prütz. (2012). PCN66 Economic Evaluation of Abiraterone Acetate as Treatment for Metastatic Castration Resistant Prostate Cancer After Failure of Docetaxel in Sweden. Value in Health. 15(4). A219–A219. 3 indexed citations

14.

Poppel, Hendrik Van & Sten Nilsson. (2008). Testosterone Surge: Rationale for Gonadotropin-Releasing Hormone Blockers?. Urology. 71(6). 1001–1006. 82 indexed citations

15.

Kälkner, Karl Mikael, Marianne Ryberg, Gabriella Cohn‐Cedermark, et al.. (2007). Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: A 6-year follow-up. Acta Oncologica. 46(7). 909–917. 46 indexed citations

16.

Srigley, John R., Mahul B. Amin, Liliane Boccon‐Gibod, et al.. (2005). Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives. Scandinavian Journal of Urology and Nephrology. 39(sup216). 8–19. 31 indexed citations

17.

Carlsson, Marianne, et al.. (2002). Self-perceived Physical, Psychologic, and General Symptoms in Survivors of Testicular Cancer 3 to 13 Years After Treatment. Cancer Nursing. 25(3). 187–195. 44 indexed citations

18.

Wester, Kenneth, Anna Sjöström, Anders Holmberg, et al.. (1998). Expression of epidermal growth factor receptor in urinary bladder cancer metastases. International Journal of Cancer. 76(2). 189–193. 1 indexed citations

19.

Wester, Kenneth, Anders Holmberg, Sten Nilsson, et al.. (1998). Expression of epidermal growth factor receptor in urinary bladder cancer metastases. International Journal of Cancer. 76(2). 189–193. 41 indexed citations

20.

Nilsson, Sten, et al.. (1997). E4, A New Monoclonal Antibody Identifying a Human Prostatic Cell Surface Antigen. Cancer Biotherapy and Radiopharmaceuticals. 12(6). 395–403. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact